Lilly cuts Foundayo self-pay prices on two doses through year end

Eli Lilly has temporarily cut the cash price on two doses of Foundayo (orforglipron), its oral GLP-1 pill. The company's coverage and savings page now states that "through December 31, 2026, the price of the 2.5 mg dosage is temporarily reduced to $149 per month and the price of the 5.5 mg dosage is temporarily reduced to $199 per month." ^[1]

Those are cuts from what the same page calls the regular self-pay prices: $199 for 2.5 mg and $299 for 5.5 mg. ^[1] Lilly does not publish a start date for the reduction on the page, and has given no public reason for it.

What the terms page says

The page lists regular one-month self-pay prices as $149 for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg. A month is defined as 30 days, and the page notes that additional taxes and fees may apply. ^[1] With the temporary reduction in place, the top of the page advertises self-pay "starting at $149 per month" for the 0.8 mg and 2.5 mg dosages, with a footnote saying the 2.5 mg price is temporarily reduced through 12/31/2026. ^[1]

Separate prices apply through the Foundayo Savings Card. Patients with commercial drug insurance that covers Foundayo can pay as little as $25 for a 1-, 2-, or 3-month fill, with savings capped at $100 per 1-month fill, $200 per 2-month fill, $300 per 3-month fill, and a separate annual cap of $1,000 per calendar year. The card can be used for up to 10 fills per calendar year and expires 12/31/2026. ^[1] People with commercial insurance that does not cover Foundayo are pointed to the same dollar figures as the self-pay tiers: $149 for 0.8 mg and 2.5 mg, $199 for 5.5 mg, and $299 for 9 mg, 14.5 mg, and 17.2 mg. ^[1]

Government beneficiaries, including people on Medicare, Medicaid, TRICARE, and VA coverage, are excluded from the savings card. ^[1] Eligible Medicare Part D patients with a Foundayo prescription for weight management are directed instead to a Medicare GLP-1 Bridge Program listed at $50 per month, which the page says is not a guarantee of coverage. ^[1]

The higher doses work differently. The page says patients automatically receive a $299 purchase offer on a first purchase of the 14.5 mg or 17.2 mg doses, and that to stay eligible they must complete the refill purchase within 45 days of the delivery or received date of the previous fill. Miss that window, and the offer does not apply. ^[1]

What patients are reporting

Members of the r/FoundayoPill community reported the new prices showing up on September 1, with some saying LillyDirect texted customers that day. Several people who had filled a prescription days earlier said they received refunds of the difference after contacting LillyDirect. ^[2] The September 1 date and the refunds are consumer reports, not stated Lilly policy, and the thread's text was not retrievable for direct verification. ^[2]

Lilly's own terms do describe a post-transaction reimbursement path, but it is written narrowly: it applies when savings could not be applied at the point of sale and Lilly could not verify eligibility, and claims go through an online portal or a mailed claim form. ^[1]

Why it matters for patients

For someone paying cash at the 5.5 mg dose, the difference is $100 a month, or $1,200 over a year at that price. At 2.5 mg it is $50 a month. Those are the two lower-middle doses, so the cut mainly affects people early in treatment or staying at a lower dose rather than those at 9 mg and above, where prices are unchanged at $299 and $349. ^[1]

The reduction is explicitly temporary and tied to a calendar date. Lilly also reserves the right to terminate, rescind, revoke, or amend the offer "at any time, with or without notice, for any reason." ^[1] Budgeting on the reduced price assumes it lasts, and the terms do not promise that.

What happens next

December 31, 2026 is the stated end date for both the temporary price cut and the Foundayo Savings Card. ^[1] Nothing has been published about what the 2.5 mg and 5.5 mg self-pay prices will be in 2027, or whether the reduction will be extended.